Know Cancer

forgot password

Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Phase 1/Phase 2
18 Years
Open (Enrolling)
Malignant Glioma

Thank you

Trial Information

Phase I/II Study of LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

- Each treatment cycle lasts 28 days (four weeks). LBH589 is taken orally three times
per week (i.e. Monday-Wednesday-Friday or Tuesday-Thursday-Sunday) every other week.
Since we are looking for the highest dose of LBH589 that can be given safely to people
who are also taking bevacizumab, not everyone who participates in this study will
receive the same amount of the drug. The dose of LBH589 given will depend on the
number of participants who have been enrolled and how well they tolerated their doses.
The dose of bevacizumab will be the same for everyone.

- On days 1 and 15 of each cycle, bevacizumab will be given as an infusion intravenously
in the clinic.

- The following tests and procedures will be performed at time intervals specified in the
protocol: physical and neurological examination; assessments of the tumor by MRI or CT
scan; routine blood tests; routine urine tests; pregnancy test for women of child
bearing potential; research blood tests and an EKG.

Inclusion Criteria:

- Provide written informed consent prior to participation in the study and any related
procedures being performed.

- Agreed to and signed an authorization for the release of their protected health

- Must be 18 years of age or older

- Karnofsky Performance Status 60 or greater

- Life expectancy of at least 8 weeks

- Histologic diagnosis of anaplastic astrocytoma (AA), anaplastic oligodendroglioma
(AO), or anaplastic mixed oligoastrocytoma (AMO) (Patients are eligible if the
original histology was lower-grade glioma)

** NOTE: new accruals to patients diagnosed glioblastoma (GBM) / gliosarcoma have
been placed on hold.**

- Unequivocal progression by magnetic resonance imaging (MRI) or computed tomography
(CT) scan. A scan must be performed within 14 days prior to registration and on a
steroid dose that has been stable for at least 5 days. (Patients with recurrence who
undergo resection and are left without measurable or evaluable disease are eligible.)

- Patients must have failed prior radiation therapy and must have an interval of
greater than or equal to 60 days from the completion of radiation therapy to study

- Patients must have recovered from the toxic effects of prior therapy. Residual
toxicity from any previous treatment must be Grade 1 or less.

- Sufficient time for recovery from prior therapy: 28 days from any investigational
agent, 28 days from prior cytotoxic therapy(except 23 days from prior temozolomide,
14 days from vincristine, 42 days from nitrosoureas, 21 days from procarbazine
administration), and 7 days for non-cytotoxic agents.

- Patients with prior therapy that included interstitial brachytherapy or stereotactic
radiosurgery must have confirmation of true progressive disease rather than radiation
necrosis based upon positron emission tomography (PET), Thallium scanning, MR
spectroscopy or surgical documentation of disease.

- Subjects who have undergone recent resection of recurrent or progressive tumor will
be eligible as long as all of the following conditions apply: a) prior to initiating
therapy, 4 weeks must have elapsed since surgery (Subjects must have recovered from
surgical-related trauma. Wound healing needs to have occurred.) b) residual disease
following resection of recurrent malignant glioma is not mandated for eligibility. To
assess the extent of residual disease postoperatively, a MRI or CT should be done at
least 4 weeks postoperatively and within 14 days prior to registration.

- Clinical laboratory tests within 14 days prior to enrollment meeting the criteria
listed in the protocol

- Cardiology assessment: Baseline MUGA or Echocardiogram must demonstrate LVEF 50% or

- Electrocardiogram: A single screening ECG, taken within 14 days of registration, will
be performed to assess study eligibility. Patients whose single QTc interval is ≤ 450
msec are eligible. Patients whose QTc interval is > 460 msec are ineligible. If the
result is > 450 msec and ≤ 460 msec, two additional ECG readings are to be performed,
each one separated by at least 5 minutes; in this case to be eligible, each
individual QTc interval must be ≤ 460 msec and the average of the QTc intervals must
be ≤ 450 msec.

- Patient is non-hypertensive or has well-controlled hypertension (systolic blood
pressure of < 140mm Hg or diastolic pressure < 90 mm Hg).

- Female subjects of childbearing potential must have a negative pregnancy test
confirmed both at screening and within 48 hours prior to dosing with the study drug

- Female subjects of childbearing potential and male subjects with female partner of
childbearing potential must agree to use a medically accepted method of contraception
while receiving protocol-specified medication, and for 3 months after stopping the

- Subjects must be free of any clinically relevant disease (other than glioma) that
would, in the Investigator's opinion, interfere with the conduct of the study or
study evaluations.

- Subjects must be able to adhere to the dosing and visit schedules, and agree to
record medication times accurately and consistently in a daily diary.

PHASE I Inclusion Criteria (the following modifications to the general eligibility
criteria apply to Phase I patients only):

• Patients may have been treated for any number of prior relapses. Relapse is defined as
progression following initial therapy

PHASE II Inclusion Criteria (phase II patients must meet the general eligibility criteria
as well as the following):

- Patients may have had treatment for no more than 2 prior relapses. (The intent
therefore is that patients had no more than 3 prior therapies: initial and treatment
for 2 relapses.)

- It is mandatory that 15 unstained paraffin slides or 1 representative tissue block be
available from original surgery or definitive surgery or the surgery closest to
initiation of this clinical trial.

Exclusion Criteria:

- Subject has received previous therapy with anti-VEGF targeted agents or with any
histone deacetylase inhibitors. (Prior treatment with valproic acid for seizures is
allowed but requires a washout of at least 14 days prior to starting LBH589.)
Although concomitant use of the following drugs is not allowed on study, previous use
is allowed, provided patients meet the following mandatory washout periods:

i. Drugs w/ risk of causing TdP = 72 hrs; ii. Warfarin = 7 days.

- History of grade 2 thrombocytopenia or grade 3 neutropenia on any prior regimen.

- Presence of ≥ grade 2 peripheral neuropathy.

- Bleeding diathesis or coagulopathy

- History of intratumoral or peritumoral hemorrhage if deemed significant by the
treating physician

- Treatment with warfarin. (For patients requiring anticoagulation therapy, only
therapeutic low molecular weight heparin or factor Xa inhibitors are permitted.)

- Patients who have received any investigational drug or undergone major surgery < 4
weeks prior to starting study drug or who have not recovered from side effects of
such therapy

- Any significant medical illnesses that in the investigator's opinion cannot be
adequately controlled with appropriate therapy or would compromise the patient's
ability to tolerate this therapy

- Patients with any disease that will obscure toxicity or dangerously alter drug

- Patients with a history of any other cancer (except non-melanoma skin cancer or
carcinoma in-situ of the cervix), unless in complete remission and has not received
treatment for that particular disease for a minimum of 3 years

- Impaired cardiac function as detailed in the protocol

- Uncontrolled hypertension (systolic blood pressure >/= 140 mmHg and/or diastolic
blood pressure >/= 90 mmHg) and/or prior history of hypertensive crisis or
hypertensive encephalopathy

- Significant vascular disease within 6 months prior to Day 1

- History of stroke or transient ischemic attack within 6 months prior to Day 1

- Patients with unresolved diarrhea > CTCAE grade 1

- Patients with INR > 1.5

- Patients with major surgery or a significant traumatic injury within 28 days prior to
Day 1

- Patients with any condition that impairs their ability to swallow and/or absorb pills

- Concomitant use of drugs with a risk of causing torsades de pointes

- Concomitant use of CYP3A4 inhibitors during the treatment phase of the study and
within 72 hours prior to starting treatment

- Concomitant use of potent CYP3A4/5 inducers during the treatment phase of the study
and within 2 weeks prior to starting treatment

- Concomitant use of any anti-cancer therapy or radiation therapy, or any other
investigational agent

- Patients has known human immunodeficiency virus (HIV) of hepatitis C infection
(baseline testing for HIV or hepatitis C is not required)

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to LBH589 or bevacizumab, or their excipients

- Patient is in a situation or condition that, in the opinion of the investigator, may
interfere with optimal participation in the study

- Patient has a significant history of non-compliance to medical regimens

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to Day 1

- History of abdominal fistula or gastrointestinal perforation within 6 months prior to
Day 1

- Serious, non-healing wound, active ulcer, or untreated bone fracture

- Proteinuria as demonstrated by a UPC ratio of 1.0 or greater at screening

- Subject is pregnant or intends to become pregnant during the study

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Phase I: To determine the maximum tolerated dose of LBH589 in combination with bevacizumab in this patient population.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Patrick Y. Wen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Food and Drug Administration

Study ID:




Start Date:

March 2009

Completion Date:

June 2014

Related Keywords:

  • Malignant Glioma
  • LBH589
  • bevacizumab
  • Avastin
  • Glioma



Dana-Farber Cancer Institute Boston, Massachusetts  02115
Massachusetts General Hospital Boston, Massachusetts  02114-2617
Northwestern University Chicago, Illinois  60611
Beth-Israel Deaconess Medical Center Boston, Massachusetts  
University of Virginia, Department of Neurology Charlottesville, Virginia  22908